Co-prescribing Doxepin with Paxil (Paroxetine): Critical Drug Interaction
Paroxetine significantly inhibits CYP2D6 metabolism and will substantially increase doxepin blood levels, requiring dose reduction of doxepin by approximately 50% or more when these medications are combined, with close monitoring for anticholinergic and sedative side effects.
Mechanism of Interaction
Paroxetine is a potent CYP2D6 inhibitor that saturates this enzyme early during dosing 1. The FDA label explicitly states that paroxetine can increase levels of drugs metabolized by CYP2D6 by 2- to 5-fold 2. Specifically, when paroxetine (20 mg daily) was combined with desipramine (a tricyclic antidepressant similar to doxepin), it increased desipramine concentrations by approximately 5-fold for AUC and 2-fold for peak levels 2.
Doxepin, like other tricyclic antidepressants, is primarily metabolized through CYP2D6 3. This creates a predictable and clinically significant pharmacokinetic interaction.
Clinical Implications
Dosing Adjustments Required
- Start doxepin at 50% of the usual dose when initiating with paroxetine already on board
- If adding paroxetine to existing doxepin therapy, reduce doxepin dose by at least 50% immediately
- The magnitude of interaction suggests even greater reductions may be necessary in some patients
Monitoring Parameters
Watch closely for:
- Anticholinergic toxicity: dry mouth, urinary retention, constipation, confusion, blurred vision
- Excessive sedation: particularly dangerous in elderly patients 4
- Cardiac effects: QT prolongation, arrhythmias (tricyclics have narrow therapeutic indices)
- Orthostatic hypotension
High-Risk Populations
Elderly patients are at substantially increased risk 4. Paroxetine levels are 70-80% higher in elderly patients 2, and doxepin's anticholinergic effects are particularly problematic in this population, causing confusion and cognitive impairment 4, 5.
Evidence Quality and Nuances
The FDA drug label 2 provides the strongest evidence, explicitly documenting 5-fold increases in tricyclic antidepressant levels with paroxetine co-administration. Research confirms paroxetine "induced significant elevations of approximately 50% in half-life" and "decreased clearance twofold" for imipramine, with "even more pronounced" effects on its metabolite 3.
Importantly, this interaction is predictable and unavoidable in all patients because paroxetine saturates CYP2D6 at therapeutic doses 1. Unlike some interactions that depend on genetic polymorphisms, this occurs regardless of CYP2D6 genotype.
Common Pitfalls to Avoid
- Don't assume standard tricyclic doses are safe when paroxetine is present—the interaction is substantial, not marginal
- Don't rely solely on patient symptoms to detect toxicity; therapeutic drug monitoring of doxepin levels may be warranted
- Don't forget that paroxetine's inhibitory effects persist for days after discontinuation due to its half-life
- Avoid this combination in elderly patients when possible; consider alternative antidepressants with less CYP2D6 inhibition (escitalopram, citalopram, sertraline) 6, 7
Alternative Considerations
If combination therapy is necessary for treatment-resistant depression:
- Sertraline has minimal CYP2D6 inhibition and would be safer with doxepin 6
- Escitalopram or citalopram are also safer alternatives 6, 7
- Consider switching strategies rather than augmentation when possible 8
The FDA explicitly warns about this interaction class 2, and clinical practice should reflect dose adjustments proportional to the 2- to 5-fold increase in tricyclic levels documented in pharmacokinetic studies.